GW Pharmaceuticals Market Cap 2013-2018 | GWPH
GW Pharmaceuticals market cap history and chart from 2013 to 2018. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of diluted shares outstanding. GW Pharmaceuticals market cap as of March 21, 2019 is $5.14B.
||Medical Products Manufacturing
GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.